We next investigate the expression of XBP1s in over 170 breast cancer patients' samples and the results demonstrate that XBP1s expression level is highly correlated with overall survival in the ER+ subgroup, but not in the ER− subgroup, suggesting a potential therapeutic application of XBP1 inhibitors in ER+breast cancer treatment. The gene discussed is ESR1; the disease is breast cancer.